Home   Chapter Home   Jobs   Conferences   Fellowships   Books


Drugs of interest to pathologists

Drugs related to surgical pathology


Author: Him G. Kwee, M.D. (see Reviewers/Authors page)
Revised: 18 November 2011, last major update October 2011
Copyright: (c) 2011, PathologyOutlines.com, Inc.


● Monoclonal antibody that inhibits Vascular Endothelial Growth Factor A (VEGF-A) and interferes with angiogenesis

Trade name

● Avastin

Clinical information

Approved by US Food and Drug Administration for:
● Non-small cell lung carcinoma that is locally advanced, cannot be removed by surgery, has metastasized or has recurred
● Colorectal carcinoma that has metastasized
● Renal cell carcinoma that has metastasized
● Glioblastoma that is refractory to other treatments
● Initially approved for patients with metastatic HER2/neu negative breast cancer who have not received chemotherapy; approval revoked on 18 November 2011 (New York Times November 18, 2011)

● Approximate cost: for breast and lung cancer $100,000.00 per year, for colon cancer $50,000.00 per year

Use for pathologists

● Bevacizumab should only be used if the lung carcinoma is an adenocarcinoma because it can cause severe pulmonary hemorrhage in squamous cell carcinoma
● Immunohistochemical stains for TTF1, napsinA, CK5/6 and p63 may be helpful to distinguish the two carcinomas
● TTF1 and napsinA are specific for adenocarcinoma and CK5/6 is specific for squamous cell carcinoma
● p63 is sensitive for squamous cell carcinoma, but is occasionally positive in adenocarcinoma (Am J Surg Pathol 2011;35:15)

Other reasons for distinguising lung adenocarcinoma and squamous cell carcinoma:
● Pemetrexed (Alimta) is only effective for pulmonary adenocarcinoma, not for squamous cell carcinoma
● Gemcitabine (Gemzar) is effective for squamous cell carcinoma of the lung
● EGFR mutation analysis is performed only on adenocarcinoma of the lung, not on squamous cell carcinoma, and this test may determine the need to use EGFR tyrosine kinase inhibitors such as erlotinib (Tarceva) and gefitinib (Iressa) (J Thorac Oncol 2011;6:1152)

End of Drugs > Drugs related to surgical pathology > Bevacizumab

This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.

All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com with any questions (click here for other contact information).